Literature DB >> 8141566

Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase.

T D Gootz1, P R McGuirk, M S Moynihan, S L Haskell.   

Abstract

Several substituted analogs of 7-(cis-3,5-dimethylpiperazinyl)-6,8-difluoro-5-amino-1-cyclopropyl quinolone were prepared and tested in a DNA cleavage assay with calf thymus topoisomerase II. Positioning of the methyl groups on the C-7 piperazine ring influenced potency against the mammalian enzyme; the cis-3,5-dimethyl configuration did not stimulate cleavage at drug concentrations less than or equal to 2,000 microM, while the trans configuration was active at drug levels as low as 36 microM. Removal of the cis-methyl groups produced a compound that was only sixfold less potent than the antitumor agent etoposide in stimulating enzyme-mediated DNA cleavage. The cis- and trans-methyl substitutions on the piperazine that conferred potency against the mammalian type II enzyme had little effect on bacterial DNA gyrase cleavage activity, suggesting that an asymmetric barrier exists with the mammalian enzyme which influences productive quinolone interaction, favoring the less bulky trans-3,5-dimethylpiperazine substituent at C-7.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8141566      PMCID: PMC284408          DOI: 10.1128/AAC.38.1.130

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDa.

Authors:  U Schomburg; F Grosse
Journal:  Eur J Biochem       Date:  1986-11-03

4.  Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase.

Authors:  R Lynn; G Giaever; S L Swanberg; J C Wang
Journal:  Science       Date:  1986-08-08       Impact factor: 47.728

5.  Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.

Authors:  T Miyamoto; J Matsumoto; K Chiba; H Egawa; K Shibamori; A Minamida; Y Nishimura; H Okada; M Kataoka; M Fujita
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

6.  Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

Authors:  M J Robinson; B A Martin; T D Gootz; P R McGuirk; M Moynihan; J A Sutcliffe; N Osheroff
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

7.  Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.

Authors:  M J Robinson; B A Martin; T D Gootz; P R McGuirk; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.

Authors:  S H Elsea; N Osheroff; J L Nitiss
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

9.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.

Authors:  S J Froelich-Ammon; P R McGuirk; T D Gootz; M R Jefson; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

  10 in total
  5 in total

1.  Antitrypanosomal activity of fluoroquinolones.

Authors:  E Nenortas; C Burri; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.

Authors:  F L Alovero; X S Pan; J E Morris; R H Manzo; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.

Authors:  J D Vrany; P S Stewart; P A Suci
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.

Authors:  Hamada H H Mohammed; Amer Ali Abd El-Hafeez; Kareem Ebeid; Aml I Mekkawy; Mohammed A S Abourehab; Emad I Wafa; Suhaila O Alhaj-Suliman; Aliasger K Salem; Pradipta Ghosh; Gamal El-Din A Abuo-Rahma; Alaa M Hayallah; Samar H Abbas
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.